Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Clearmind Medicine (Nasdaq: CMND) has secured a securities purchase agreement with institutional investors for convertible promissory notes worth up to $10 million. The initial closing includes notes worth $555,556 for a purchase price of $500,000, with an additional $1.94 million to be issued following SEC registration.
The agreement allows Clearmind to request additional note purchases of up to $2.5 million per quarter, totaling $7.5 million. The notes will be issued at 90% of principal value, carrying a 4% interest rate (14% upon default), with repayment in 10 monthly installments starting 18 months after issuance. The notes are convertible into common shares at a variable price not below $0.20.
Clearmind Medicine (Nasdaq: CMND) ha ottenuto un accordo di acquisto titoli con investitori istituzionali per note promissorie convertibili fino a un valore di 10 milioni di dollari. La chiusura iniziale comprende note per 555.556 dollari a un prezzo di acquisto di 500.000 dollari, con ulteriori 1,94 milioni di dollari da emettere dopo la registrazione presso la SEC.
L’accordo permette a Clearmind di richiedere ulteriori acquisti di note fino a 2,5 milioni di dollari per trimestre, per un totale di 7,5 milioni. Le note saranno emesse al 90% del valore nominale, con un tasso di interesse del 4% (14% in caso di inadempienza), e con rimborso in 10 rate mensili a partire da 18 mesi dall’emissione. Le note sono convertibili in azioni ordinarie a un prezzo variabile non inferiore a 0,20 dollari.
Clearmind Medicine (Nasdaq: CMND) ha asegurado un acuerdo de compra de valores con inversores institucionales para notas promisorias convertibles por hasta 10 millones de dólares. El cierre inicial incluye notas por 555.556 dólares, a un precio de compra de 500.000 dólares, con otros 1,94 millones de dólares que se emitirán tras la registración ante la SEC.
El acuerdo permite a Clearmind solicitar compras adicionales de notas de hasta 2,5 millones de dólares por trimestre, para un total de 7,5 millones. Las notas se emitirán al 90% de su valor nominal, con una tasa de interés del 4% (14% en caso de incumplimiento), y serán reembolsadas en 10 cuotas mensuales a partir de los 18 meses después de la emisión. Las notas son convertibles en acciones comunes a un precio variable que no debe ser inferior a 0,20 dólares.
Clearmind Medicine(Nasdaq: CMND)은 기관 투자자들과의 증권 매입 계약을 체결했으며, 최대 1000만 달러 규모의 전환 가능 어음을 발행합니다. 최초 체결은 55만5,556달러 상당의 어음으로 50만 달러의 매입가로 구성되며, SEC 등록 후 추가로 194만 달러가 발행될 예정입니다.
계약에 따라 Clearmind는 분기당 250만 달러의 추가 어음 매입을 요청할 수 있어 총액은 750만 달러에 이릅니다. 어음은 원금의 90%로 발행되며 이자율은 4%이고, 부도 시 14%입니다. 발행일로부터 18개월 뒤 시작하는 10개월 상환으로 이행됩니다. 어음은 변동 가격으로 보통주로 전환 가능하며 전환가액은 0.20달러 미만으로는 설정되지 않습니다.
Clearmind Medicine (Nasdaq: CMND) a obtenu un accord d’achat de titres avec des investisseurs institutionnels pour des notes promisoires convertibles d’une valeur allant jusqu’à 10 millions de dollars. La clôture initiale comprend des notes pour 555 556 dollars, à un prix d’achat de 500 000 dollars, avec 1,94 million de dollars supplémentaires à émettre après l’enregistrement auprès de la SEC.
L’accord permet à Clearmind de demander des achats additionnels de notes jusqu’à 2,5 millions de dollars par trimestre, soit un total de 7,5 millions. Les notes seront émises à 90% de leur valeur nominale, avec un taux d’intérêt de 4% (14% en cas de défaut), et remboursables en 10 versements mensuels à partir de 18 mois après l’émission. Les notes sont convertibles en actions ordinaires à un prix variable ne descendant pas en dessous de 0,20 dollars.
Clearmind Medicine (Nasdaq: CMND) hat mit institutionellen Investoren eine Wertpapierkaufvereinbarung für wandelbare Darlehen im Wert von bis zu 10 Millionen Dollar getroffen. Der anfängliche Abschluss umfasst Anleihen im Wert von 555.556 Dollar zu einem Kaufpreis von 500.000 Dollar, mit weiteren 1,94 Millionen Dollar, die nach der SEC-Registrierung ausgegeben werden sollen.
Der Vertrag erlaubt Clearmind, zusätzliche Anleihekäufe bis zu 2,5 Millionen Dollar pro Quartal zu beantragen, insgesamt 7,5 Millionen. Die Anleihen werden zum 90% des Nennwerts ausgegeben, mit einem Zinssatz von 4% (14% bei Verzug), und sie werden in 10 monatlichen Raten beginnend nach 18 Monaten ausgezahlt. Die Anleihen sind in Stammaktien zu einem variablen Preis wandelbar, der nicht unter 0,20 USD liegt.
أبرمت Clearmind Medicine (Nasdaq: CMND) اتفاقية شراء أوراق مالية مع مستثمرين مؤسسيين لسندات وعود قابلة للتحويل تصل قيمتها حتى 10 ملايين دولار. الإغلاق الأول يتضمن سندات بقيمة 555,556 دولارًا بسعر شراء قدره 500,000 دولار، مع إصدار إضافي قدره 1,94 مليون دولار سيصدر بعد تسجيل لدى هيئة الأوراق المالية.
تسمح الاتفاقية لـ Clearmind بطلب شراء سندات إضافية حتى 2,5 مليون دولار لكل ربع سنة، ليصل الإجمالي إلى 7,5 مليون دولار. ستصدر هذه السندات بنسبة 90% من قيمتها الاسمية، وبمعدل فائدة 4% (14% في حالة التخلف عن السداد)، وتُسدّد على مدار 10 أقساط شهرية ابتداءً من 18 شهراً بعد الإصدار. يمكن تحويل السندات إلى أسهم عادية بسعر تحويل متغير لا يقل عن 0,20 دولار.
Clearmind Medicine（纳斯达克：CMND）已与机构投资者就可转换本票达成证券购买协议，金额最高可达 1000万美元。初次交割包括价值 55.5556万美元的本票，购买价为 50万美元，在向美国证券交易委员会注册后，另发行约 194万美元。
该协议允许 Clearmind 每季度最多提出 250万美元的额外本票购买请求，总额为 750万美元。本票按本金的 90%发行，年利率为 4%（违约时为 14%），发行后 18 个月开始分期偿还，共 10 期。本票可按变动价格转换为普通股，转换价格不得低于 0.20 美元。
- Secured access to up to $10 million in funding through convertible notes
- Flexible funding structure allowing quarterly draws of up to $2.5 million
- 90% purchase price represents favorable terms for the company
- Relatively low initial interest rate of 4% on the notes
- Potential dilution for existing shareholders through note conversion
- High default interest rate of 14% poses significant risk
- Variable conversion price adds uncertainty to potential dilution impact
- Monthly repayment structure starting after 18 months could strain cash flow
Insights
Clearmind secured flexible $10M funding through convertible notes at discounted rates with variable conversion features, strengthening their capital position but potentially diluting shareholders.
Clearmind Medicine has secured a strategic funding arrangement providing access to up to
The financing terms reveal several important elements: the notes are issued at
This arrangement provides Clearmind with significant financial flexibility and runway extension, especially valuable for clinical-stage biotechs with limited revenue. The structure allows the company to draw capital as needed rather than diluting immediately. However, the
Most significantly, management's stated intention to explore "potential acquisitions" signals a possible strategic pivot or expansion beyond their current psychedelic-derived therapeutics pipeline, potentially transforming the company's risk profile and development timeline.
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into securities purchase agreements (the “SPAs”) with institutional investors (the “Holders”). Pursuant to the SPAs, the Company may issue and sell, from time to time, convertible promissory notes (the “Notes”) in an aggregate principal amount of up to
Aegis Capital Corp. acted as financial advisor for the transaction.
Pursuant to and subject to the conditions set forth in the SPAs, following the effectiveness of a registration statement with the Securities and Exchange Commission (the “Second Initial Closing”), the Company shall issue and sell additional Notes in the aggregate principal amount of
In addition, if at any time after the Second Initial Closing, the daily trading volume of the Company’s common shares is at least
Each Note will be issued at a purchase price equal to
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses it discusses the terms and potential future issuances of Notes under the SPAs, the Company’s intended use of proceeds and its exploration of strategic opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the total value of Clearmind Medicine's (CMND) new securities purchase agreement?
What are the key terms of CMND's convertible notes issued in September 2025?
How much initial funding did Clearmind Medicine receive in the First Initial Closing?
How will Clearmind Medicine (CMND) use the proceeds from the convertible notes?
What is the quarterly funding limit for CMND under this agreement?
